SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS
申请人:Su Wei-Guo
公开号:US20140121200A1
公开(公告)日:2014-05-01
Provided are pyridopyrazine compounds of formula (1), pharmaceutical compositions thereof and methods of use therefore, wherein R
1
, R
2
, R
3
, R
4
and m are as defined in the specification.
[EN] SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS<br/>[FR] PYRIDOPYRAZINES SUBSTITUÉES EN TANT QUE NOUVEAUX INHIBITEURS DE SYK
申请人:HUTCHISON MEDIPHARMA LTD
公开号:WO2012167423A1
公开(公告)日:2012-12-13
Provided are certain pyridopyrazine compounds, pharmaceutical compositions thereof and methods of use therefor.
提供了某些吡啶吡嗪化合物,其药物组成物以及使用方法。
[EN] HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QUE RÉCEPTEUR DE DÉCLENCHEMENT EXPRIMÉ SUR DES AGONISTES DE CELLULES MYÉLOÏDES 2 ET PROCÉDÉS D'UTILISATION
申请人:AMGEN INC
公开号:WO2021226629A1
公开(公告)日:2021-11-11
The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
Substituted pyrido[3,4-b]pyrazines as Syk inhibitors
申请人:HUTCHISON MEDIPHARMA LIMITED
公开号:US10052330B2
公开(公告)日:2018-08-21
Provided are pyridopyrazine compounds of formula (I), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, R4 and m are as defined in the specification.
本发明提供了式 (I) 的吡啶并吡嗪化合物、其药物组合物及其使用方法,其中 R1、R2、R3、R4 和 m 如说明书中所定义。